Article Text

SAT0412 Disease Activity in Patients with Primary SjÖgren's Syndrome Followed by Spanish Rheumatology Departments
  1. M. Fernandez Castro1,
  2. J.L. Andreu2,
  3. A. Olivé3,
  4. J. Rosas4,
  5. V. Martínez Taboada5,
  6. C. Sánchez-Piedra6,
  7. L. Romaní7,
  8. S. Melchor8,
  9. B. Moreira9,
  10. E. Raya10,
  11. M. Rodriguez Lόpez11,
  12. N. Cid12,
  13. E. Júdez13,
  14. C. Moriano14,
  15. V. Torrente15,
  16. H. Corominas16,
  17. B. García Magallόn17
  18. on behalf of Sjögren's Project, Systemic Autoimmune Disease's Group of the Spanish Rheumatology Society
  1. 1Hospital Infanta Sofía
  2. 2Hospital Puerta de Hierro, Madrid
  3. 3Hospital Germans Trias i Pujol, Badalona
  4. 4Hospital de Marina Baixa, Villajoyosa
  5. 5Hospital Marqués de Valdecilla, Santander
  6. 6Spanish Rheumatology Society's Research Unit, Madrid
  7. 7Hospital Virgen de las Nieves, Granada
  8. 8Hospital Virgen de las Nieves, Madrid
  9. 9Hospital de Sierrallana, Torrelavega
  10. 10Hospital Clínico San Cecilio, Granada
  11. 11Hospital de Meixoeiro, Vigo
  12. 12Hospital de Valme, Sevilla
  13. 13Hospital de Albacete, Albacete
  14. 14Hospital de Leόn, Leόn
  15. 15Hospital de L'Hospitalet, Hospitalet de Llobregat
  16. 16Hospital Sant Joan Despí Moisès Broggi, Barcelona
  17. 17Hospital Miguel Servet, Zaragoza, Spain


Background Primary Sjögren syndrome (pSS) is a systemic autoimmune disease affecting primarily the exocrine glandular system. More than half of the patients with 10 or more years of follow up show extra-glandular manifestations, which will be determinant for the prognosis. Several validated methods are available in order to assess activity in pSS, including the Sjogren's Syndrome Disease Activity Index (SSDAI) and the EULAR Sjogren's Syndrome Disease Activity Index ESSDAI).

Objectives The aim of our study was to evaluate disease activity in a representative cohort of patients followed in rheumatology departments.

Methods We conducted a multicenter descriptive transversal study of a cohort of Spanish pSS patients fulfilling European/American criteria. It is a randomised register of patients obtained from 33 spanish rheumatology departments. We used SSDAI and ESSDAI in every patient. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates, with their deviations and interquartile ranges (p25-p75).

Results A total of 437 patients were included. Median score for SSDAI was 1 (0-3, p25-p75) and for ESSDAI was 2 (0-4, p25-p75). More than 95% of patients did not show fever, night sweating or weight loss. Twenty percent of them manifested weakness. Less than 5% of patients suffered glandular inflammatory disease or lymphadenopathy. Thirty two percent referred joint pain with stiffness but only 3% had true sinovitis. Fourteen patients (3%) showed cutaneous involvement. Fourteen percent of patients developed pleural involvement. High resolution CT was performed in 89 patients and showed interstitial disease in less than 4% percent of them. Serum creatinine was elevated in 3% of the cases. Seven patients developed tubular acidosis and 2 patients glomerular involvement. Less than two percent of patients had central nervous system involvement and 3% had peripheral nervous system involvement. Twenty seven percent of patients developed some kind of cytopenia: anaemia 14%, lymphopenia 14%, neutropenia 7% and thrombocytopenia, 9%. Twenty three percent had monoclonal component and/or hypoclomplementemia and/or hypergammaglobulinemia and/or high Ig G levels. Four percent showed cryoglobulinemia and/or hypergammaglobulinemia and/or high Ig G levels and/or recent hypogammaglobulinemia or a recent IgG levels fall.

Conclusions pSS patients show low scores at the systemic damage indexes. Most affected domains were haematological, biological and articular. Considering parenchymatous and pleural involvement, lung is the organ most frequently involved.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.